Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 19/20 | 0.73 |
| ▸ | ABCB1 | P08183 | 12/20 | 0.73 |
| ▸ | ABCC1 | P33527 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29126710 | 0.88 | ABCG2 (0.61) | ABCG2ABCB1ABCC1MEN1LMNA | |
| SCHEMBL3109746 | 0.88 | ABCG2 (0.74) | ABCG2ABCB1ABCC1MEN1LMNA | |
| SCHEMBL2256420 | 0.86 | POLB (0.67) | ABCG2ABCB1ABCC1MEN1TP53 | |
| SCHEMBL3112389 | 0.85 | ABCG2 (0.71) | ABCG2ABCB1ABCC1MEN1LMNA | |
| SCHEMBL8899168 | 0.84 | ABCG2 (0.72) | ABCG2ABCB1ABCC1MEN1LMNA | |
| SCHEMBL22273241 | 0.84 | ABCG2 (1.00) | ABCG2ABCB1ABCC1MEN1LMNA | |
| SCHEMBL28478249 | 0.84 | ABCG2 (0.65) | ABCG2ABCB1ABCC1MEN1LMNA | |
| Hydrochloric Acid SCHEMBL8907536 | 0.83 | ABCG2 (0.70) | ABCG2ABCB1ABCC1MEN1LMNA | |
| SCHEMBL29126705 | 0.83 | ABCG2 (0.53) | ABCG2ABCB1ABCC1MEN1LMNA | |
| SCHEMBL20042056 | 0.83 | ABCG2 (0.53) | ABCG2ABCB1ABCC1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| EP-1833482-A2 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006074147-A2 | NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | ABCG2 1381/4885ABCB1 650/4885ABCC1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.